It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
BRCA2 and its interactors are required for meiotic homologous recombination (HR) and fertility. Loss of HSF2BP, a BRCA2 interactor, disrupts HR during spermatogenesis. We test the model postulating that HSF2BP localizes BRCA2 to meiotic HR sites, by solving the crystal structure of the BRCA2 fragment in complex with dimeric armadillo domain (ARM) of HSF2BP and disrupting this interaction in a mouse model. This reveals a repeated 23 amino acid motif in BRCA2, each binding the same conserved surface of one ARM domain. In the complex, two BRCA2 fragments hold together two ARM dimers, through a large interface responsible for the nanomolar affinity — the strongest interaction involving BRCA2 measured so far. Deleting exon 12, encoding the first repeat, from mBrca2 disrupts BRCA2 binding to HSF2BP, but does not phenocopy HSF2BP loss. Thus, results herein suggest that the high-affinity oligomerization-inducing BRCA2-HSF2BP interaction is not required for RAD51 and DMC1 recombinase localization in meiotic HR.
BRCA2 and its interactor HSF2BP are required for meiotic recombination. Here, the authors define the interaction structurally, revealing that a repeat in BRCA2 binds two HSF2BP units, increasing the affinity. This region is, however, not essential for mouse meiosis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Veerman Jasper 3
; Paul, Maarten W 3
; Le, Du Marie-Hélène 1 ; Sleddens-Linkels Esther 4 ; van Rossum-Fikkert Sari E 5 ; van Loon Yvette 3 ; Felipe-Medina, Natalia 6 ; Pendas, Alberto M 6
; Maas, Alex 7 ; Essers Jeroen 8 ; Legrand, Pierre 9
; Baarends, Willy M 4
; Kanaar Roland 3 ; Zinn-Justin, Sophie 1 ; Zelensky, Alex N 3
1 CEA, CNRS, Uni Paris-Sud, Uni Paris-Saclay, Institute for Integrative Biology of the Cell (I2BC), Gif-sur-Yvette, France (GRID:grid.457334.2)
2 Erasmus University Medical Center, Department of Developmental Biology, Oncode Institute, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
3 Erasmus University Medical Center, Department of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
4 Erasmus University Medical Center, Department of Developmental Biology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
5 Erasmus University Medical Center, Department of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X); Erasmus University Medical Center, Department of Radiation Oncology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
6 Centro de Investigación del Cáncer and Instituto de Biología Molecular y Celular del Cáncer (CSIC-Universidad de Salamanca), Molecular Mechanisms Program, Salamanca, Spain (GRID:grid.11762.33) (ISNI:0000 0001 2180 1817)
7 Erasmus University Medical Center, Department of Cell Biology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
8 Erasmus University Medical Center, Department of Molecular Genetics, Oncode Institute, Erasmus MC Cancer Institute, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X); Erasmus University Medical Center, Department of Radiation Oncology, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X); Erasmus University Medical Center, Department of Vascular Surgery, Rotterdam, The Netherlands (GRID:grid.5645.2) (ISNI:000000040459992X)
9 Synchrotron SOLEIL, L’Orme des Merisiers, Gif-sur-Yvette, France (GRID:grid.426328.9)




